Chronic lymphocytic leukaemia (CLL)

2005-05-01   Kavita S Reddy 

1.Kaiser Permanente Southern California, 4580 ElectronicPlace, Los Angeles, CA 90039, USA
2.Laboratoire Pasteur-Cerba, 95066, Cergy-Pontoise, France

Clinics and Pathology

Disease

Chronic lymphoproliferation

Phenotype stem cell origin

B-cell disease; the existence of rare cases of T-CLL has been debated

Epidemiology

Annual incidence 30/106; represents 70% of lymphoid leukaemias, 1/4 of all leukaemias; median age: 60-80 yrs, 2M/1F

Clinics

Diagnosis is often delayed, due to the lack of symptoms (therefore, median survival from the begining of the disease may be much more than median survival from diagnosis). The patient may present with enlarged lymph nodes, splenomegaly, lymphocytosis > 4 5 X 109/l; hypogammaglobulinemia in 60%

Cytology

Typically, proliferation of mature small lymphocytes of normal morphology; lymphocytes with more abundant cytoplasm may be present. When prolymphocytes are 10% or greater they are classified as chronic lymphocytic leukaemia-prolymphocytic leukaemia.

The main immunophenotypic features that define B-CLL are: the predominant population shares B-cell markers CD19, CD20, and CD23 with the CD5 antigen, in the absence of other pan-T-cell markers; the B-cell is monoclonal with regard to expression of either kappa or lambda; and surface immunoglobulin (slg) is of low density. Not only are these characteristics generally adequate for a precise diagnosis, but, importantly, they distinguish CLL from uncommon disorders such as PLL, hairy-cell leukemia, mantle-cell lymphoma, and other lymphomas. Further, the Matutes score based on the most common marker profile in CLL, CD5+, CD23+, FMC7- and weak expression (+/-) of surface immunoglobulin (SIg) and CD22, can distinguish between typical and atypical CLL by assigning scores that range from 5 (typical of CLL) to 0 (atypical for CLL).

Treatment

Binet staging is used for therapeutic intervention. The treatments options are: watchful waiting for symptoms, radiation therapy, chemotherapy, surgery such as splenectomy. Those being tested in clinical trails are monoclonal antibodies, chemotherapy with stem cell transplant.

Prognosis

Evolution: unrelated causes and disease-related infections are the 2 major causes of death ; others: autoimmune hemolytic anaemia and thrombocytopenia; transformation into Richters disease or into prolymphocytic leukaemia (in 10%). Some patients with CLL survive for many years without therapy with minimal signs and symptoms, during the entire disease course and have a survival time similar to age-matched controls, whereas others have a rapidly deteriorating blood counts and organomegaly. Rai et al and Binet et al devised staging: less than 3 lymph nodes, HGB

Genes Involved and Proteins

Note
genes involved as a primary event are still unknown. ATM and P53 are deleted in 11q and 17p deletions, respectively.

Bibliography

Pubmed IDLast YearTitleAuthors
33178541987Prognostic and therapeutic advances in CLL management: the experience of the French Cooperative Group. French Cooperative Group on Chronic Lymphocytic Leukemia.
155616822004Chronic lymphocytic leukemia.Byrd JC et al
86528111996National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.Cheson BD et al
157288132005Chronic lymphocytic leukemia.Chiorazzi N et al
79937921994Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias.Criel A et al
90782901997Genes and chromosomes in chronic B-cell leukemia.Crossen PE et al
111362612000Genomic aberrations and survival in chronic lymphocytic leukemia.Döhner H et al
126942512003Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia.Dewald GW et al
90782881997Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications.Dierlamm J et al
76839271993Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia.Escudier SM et al
90782911997Interphase cytogenetics in chronic lymphocytic leukemia.Garcia-Marco JA et al
28177761989Karyotypes of 33 patients with clonal aberrations in chronic lymphocytic leukaemia. Review of 216 abnormal karyotypes in chronic lymphocytic leukaemia.Huret JL et al
86839751996Trisomy 12 in chronic lymphocytic leukaemia.Matutes E et al
86030041996Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients.Matutes E et al
76871641993Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology.Que TH et al
153257012004Molecular genetics and its clinical relevance.Stilgenbauer S et al
86839741996Trisomy 12 is a rare cytogenetic finding in typical chronic lymphocytic leukemia.Woessner S et al

Citation

Kavita S Reddy

Chronic lymphocytic leukaemia (CLL)

Atlas Genet Cytogenet Oncol Haematol. 2005-05-01

Online version: http://atlasgeneticsoncology.org/haematological/2034/chronic-lymphocytic-leukaemia-(cll)

Historical Card

1997-08-01 Chronic lymphocytic leukaemia (CLL) by  Jean-Loup Huret,Hossain Mossafa 

Laboratoire Pasteur-Cerba, 95066, Cergy-Pontoise, France